Jalyn

Jalyn is a brand name of dutasteride/tamsulosin, approved by the FDA in the following formulation(s):

JALYN (dutasteride; tamsulosin hydrochloride - capsule; oral)

• 
  Manufacturer: GLAXOSMITHKLINE
  
  Approval date: June 14, 2010
  
  Strength(s): 0.5MG;0.4MG ^[RLD]

Has a generic version of Jalyn been approved?

No. There is currently no therapeutically equivalent version of Jalyn available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Jalyn. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Androstenone derivative
  Patent 5,565,467
  Issued: October 15, 1996
  Inventor(s): Batchelor; Kenneth W. & Frye; Stephen V. & Dorsey, Jr.; George F. & Mook, Jr.; Robert A.
  Assignee(s): Glaxo Wellcome Inc.
  The present invention relates to the compound of formula (I), ##STR1## also known as 17.beta.-N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5.alpha.-andros t-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparation, pharmaceutical formulations thereof and its use in the treatment of androgen responsive and mediated diseases.
  
  Patent expiration dates:
  
  
  • November 20, 2015
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Androstenone derivative
  Patent 5,846,976
  Issued: December 8, 1998
  Inventor(s): Batchelor; Kenneth William & Frye; Stephen Vernon & Dorsey, Jr.; George F. & Mook, Jr.; Robert A.
  Assignee(s): Glaxo Wellcome Inc.
  The present invention relates to the compound of formula (I), ##STR1## also known as 17.beta.-N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5.alpha.-andros t-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparation, pharmaceutical formulations thereof and its use in the treatment of androgen responsive and mediated diseases.
  
  Patent expiration dates:
  
  
  • September 17, 2013
    
    ✓ 
    Patent use: METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
  
  



• 
  Androstenones
  Patent 5,998,427
  Issued: December 7, 1999
  Inventor(s): Batchelor; Kenneth William & Frye; Stephen Vernon
  Assignee(s): Glaxo Wellcome Inc.
  The present invention relates to compounds of formula (I), wherein carbons 1 and 2 are joined by either a single or a double bond; R.sup.1 is hydrogen or methyl; R.sup.2 is hydrogen or methyl; R.sup.3 is (B) wherein X, R.sup.6, R.sup.7 and R.sup.8 are various groups, and pharmaceutically acceptable solvates thereof and their use in the treatment of androgen responsive and mediated diseases. ##STR1##
  
  Patent expiration dates:
  
  
  • September 17, 2013
    
    ✓ 
    Patent use: METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMININSTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

See also...

• Jalyn Consumer Information (Drugs.com)
• Jalyn Consumer Information (Wolters Kluwer)
• Jalyn Consumer Information (Cerner Multum)
• Jalyn Advanced Consumer Information (Micromedex)
• Dutasteride/Tamsulosin Consumer Information (Wolters Kluwer)
• Dutasteride and tamsulosin Consumer Information (Cerner Multum)
• Dutasteride and tamsulosin Advanced Consumer Information (Micromedex)